In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
University of Southern California
University of Southern California
Memorial Sloan Kettering Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Memorial Sloan Kettering Cancer Center
Incyte Corporation
TuHURA Biosciences, Inc.
Fujifilm Pharmaceuticals U.S.A., Inc.
Memgen, Inc.
Pfizer
University of Virginia
Incyte Corporation
Checkpoint Therapeutics, Inc.
Sotio Biotech Inc.
TuHURA Biosciences, Inc.
Mayo Clinic
Ohio State University Comprehensive Cancer Center
University of Florida
Immunomic Therapeutics, Inc.
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics
Pfizer
Genocea Biosciences, Inc.
AbbVie
AbbVie
University of Zurich
Incyte Corporation
Novartis
Incyte Corporation
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)
University of Southern California
ImmunoGen, Inc.